Literature DB >> 25965311

CROI 2015: Neurologic Complications of HIV Infection.

Serena S Spudich1, Beau M Ances2.   

Abstract

More than 30 years into the HIV epidemic, research efforts are focusing on better understanding how the central nervous system (CNS) is adversely affected by HIV and on improving the quality of life of HIV-infected individuals. At the 2015 Conference on Retroviruses and Opportunistic Infections, neurologic presentations concentrated on characterization of potential CNS reservoirs of HIV, the pathogenesis of HIV-associated neurocognitive disorders (HAND), diagnosis of cognitive dysfunction caused by HIV,neuroimaging biomarkers of HAND, and treatment of modifiable risk factors of HAND. Studies presented also highlighted research on CNS disorders in international, resource-limited settings, setting the stage for a growing collection of collaborative studies that will directly impact the largest concentrations of people living with HIV worldwide.

Entities:  

Mesh:

Year:  2015        PMID: 25965311      PMCID: PMC6148901     

Source DB:  PubMed          Journal:  Top Antivir Med        ISSN: 2161-5853


  6 in total

1.  Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression.

Authors:  Lucette A Cysique; Bruce J Brew
Journal:  J Neurovirol       Date:  2011-03-17       Impact factor: 2.643

2.  HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.

Authors:  R K Heaton; D B Clifford; D R Franklin; S P Woods; C Ake; F Vaida; R J Ellis; S L Letendre; T D Marcotte; J H Atkinson; M Rivera-Mindt; O R Vigil; M J Taylor; A C Collier; C M Marra; B B Gelman; J C McArthur; S Morgello; D M Simpson; J A McCutchan; I Abramson; A Gamst; C Fennema-Notestine; T L Jernigan; J Wong; I Grant
Journal:  Neurology       Date:  2010-12-07       Impact factor: 9.910

3.  Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden.

Authors:  Serena Spudich; Magnus Gisslen; Lars Hagberg; Evelyn Lee; Teri Liegler; Bruce Brew; Dietmar Fuchs; Giuseppe Tambussi; Paola Cinque; Frederick M Hecht; Richard W Price
Journal:  J Infect Dis       Date:  2011-09-01       Impact factor: 5.226

4.  Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.

Authors:  N Ciccarelli; M Fabbiani; S Di Giambenedetto; I Fanti; E Baldonero; L Bracciale; E Tamburrini; R Cauda; A De Luca; M C Silveri
Journal:  Neurology       Date:  2011-04-19       Impact factor: 9.910

5.  Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.

Authors:  Peter Derek Christian Leutscher; Chalotte Stecher; Merete Storgaard; Carsten Schade Larsen
Journal:  Scand J Infect Dis       Date:  2013-02-21

6.  Heme oxygenase-1 deficiency accompanies neuropathogenesis of HIV-associated neurocognitive disorders.

Authors:  Alexander J Gill; Colleen E Kovacsics; Stephanie A Cross; Patricia J Vance; Lorraine L Kolson; Kelly L Jordan-Sciutto; Benjamin B Gelman; Dennis L Kolson
Journal:  J Clin Invest       Date:  2014-09-09       Impact factor: 14.808

  6 in total
  4 in total

1.  Brain and Cognitive Development Among U.S. Youth With Perinatally Acquired Human Immunodeficiency Virus Infection.

Authors:  Kathleen M Malee; Renee A Smith; Claude A Mellins
Journal:  J Pediatric Infect Dis Soc       Date:  2016-12       Impact factor: 3.164

Review 2.  The role of Pannexin-1 channels and extracellular ATP in the pathogenesis of the human immunodeficiency virus.

Authors:  Daniela D'Amico; Silvana Valdebenito; Eliseo A Eugenin
Journal:  Purinergic Signal       Date:  2021-09-20       Impact factor: 3.765

3.  Neurological involvement in patients with acute/recent HIV-1 infection. A case-control study.

Authors:  Juan Ambrosioni; Francisca Artigues; David Nicolás; Judit Peñafiel; Fernando Agüero; Christian Manzardo; María Mar Mosquera; Sonsoles Sánchez-Palomino; Elisa De Lazzari; María A Marcos; Montserrat Plana; José M Miró
Journal:  J Neurovirol       Date:  2017-07-17       Impact factor: 3.739

Review 4.  The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review.

Authors:  Thomas M Gates; Lucette A Cysique
Journal:  CNS Drugs       Date:  2016-01       Impact factor: 5.749

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.